{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:25:44Z","timestamp":1772040344563,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.phrs.2025.107792","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T10:55:48Z","timestamp":1748084148000},"page":"107792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pediatric infections in the first year of life following maternal biologic exposure for autoimmune disorder treatment: A systematic review"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-8596","authenticated-orcid":false,"given":"Renee Gabrielle","family":"Fajardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-8479","authenticated-orcid":false,"given":"Akash","family":"Uddandam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-0515","authenticated-orcid":false,"given":"Jessie","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-0372","authenticated-orcid":false,"given":"Cristina","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-7854","authenticated-orcid":false,"given":"Sonia M.","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107792_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43162-021-00040-5","article-title":"Bridging autoinflammatory and autoimmune diseases","volume":"33","author":"El-Shebiny","year":"2021","journal-title":"Egypt J. Intern Med"},{"key":"10.1016\/j.phrs.2025.107792_bib2","article-title":"The prevalence of autoimmune disorders in women: a narrative review","volume":"12","author":"Angum","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2025.107792_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12348-6","article-title":"ImmGen report: sexual dimorphism in the immune system transcriptome","volume":"10","author":"Gal-Oz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107792_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.752660","article-title":"Cytokine patterns in maternal serum from first trimester to term and beyond","volume":"12","author":"Jarmund","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107792_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575197","article-title":"Maternal immunological adaptation during normal pregnancy","volume":"11","author":"Abu-Raya","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2025.107792_bib6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1186\/s12884-023-06033-2","article-title":"Association between disease activity of rheumatoid arthritis and maternal and fetal outcomes in pregnant women: a systematic review and meta-analysis","volume":"23","author":"Lv","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.phrs.2025.107792_bib7","first-page":"1123","article-title":"Systemic lupus erythematosus","volume":"2009","author":"Madhok","year":"2009","journal-title":"BMJ Clin. Evid."},{"key":"10.1016\/j.phrs.2025.107792_bib8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment algorithms in systemic lupus erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.phrs.2025.107792_bib9","first-page":"284","article-title":"Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management","volume":"94","author":"Lam","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.phrs.2025.107792_bib10","first-page":"1","article-title":"Autoimmune diseases and adverse pregnancy outcomes: an umbrella review","volume":"22","author":"Singh","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.phrs.2025.107792_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107792_bib12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinican\u2019s perspective","volume":"43","author":"Katarzyna","year":"2023","journal-title":"Rheuma Int"},{"key":"10.1016\/j.phrs.2025.107792_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2025.107792_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/1352458515623366","article-title":"Glatiramer acetate during early pregnancy: a prospective cohort study","volume":"22","author":"Herbstritt","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.phrs.2025.107792_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420951072","article-title":"Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden","volume":"13","author":"Hakkarainen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.phrs.2025.107792_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.927179","article-title":"Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: systematic review and meta-analysis","volume":"13","author":"De Castro","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.107792_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri","year":"2009","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.phrs.2025.107792_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature03727","article-title":"Design of effective immunotherapy for human autoimmunity","volume":"435","author":"Feldmann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107792_bib19","first-page":"24","article-title":"Defining the difference: what makes biologics unique","volume":"1","author":"Morrow","year":"2004","journal-title":"Biotechnol. Health"},{"key":"10.1016\/j.phrs.2025.107792_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2025.107792_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7196\/AJTCCM.2021.v27i2.117","article-title":"Adverse effects of biologic anti-inflammatory agents on the respiratory system: a review","volume":"27","author":"Joseph","year":"2021","journal-title":"Afr. J. Thorac. Crit. Care Med."},{"key":"10.1016\/j.phrs.2025.107792_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2025.107792_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(16)30422-X","article-title":"Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry","volume":"150","author":"Mahadevan","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2025.107792_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107792_bib25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjx141","article-title":"Ustekinumab drug levels in maternal and cord blood in a woman with Crohn\u2019s disease treated until 33 weeks of gestation","volume":"12","author":"Rowan","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2025.107792_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF levels in cord blood at birth are associated with anti-TNF type","volume":"12","author":"Kanis","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2025.107792_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2025.107792_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","article-title":"Immunosuppressives and biologics during pregnancy and lactation","volume":"131","author":"Puchner","year":"2019","journal-title":"Wien. Klin. Woche"},{"key":"10.1016\/j.phrs.2025.107792_bib29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.14430","article-title":"Market share and costs of biologic therapies for inflammatory bowel disease in the USA","volume":"47","author":"Yu","year":"2018","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107792_bib30","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2025.107792_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/apt.15956","article-title":"In utero exposure to thiopurines\/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark","volume":"52","author":"N\u00f8rg\u00e5rd","year":"2020","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107792_bib32","doi-asserted-by":"crossref","first-page":"23714","DOI":"10.1136\/bmjopen-2018-023714","article-title":"Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study","volume":"9","author":"Tsao","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2025.107792_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223603","article-title":"Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study","volume":"14","author":"Chambers","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107792_bib34","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/art.40536","article-title":"Serious infections in rheumatoid arthritis offspring exposed to tumor necrosis factor inhibitors: a cohort study","volume":"70","author":"Vinet","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.phrs.2025.107792_bib35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00404-022-06463-x","article-title":"Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare","volume":"306","author":"Allen","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.phrs.2025.107792_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40263-013-0113-7","article-title":"Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review","volume":"27","author":"Fragoso","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2025.107792_bib37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/apt.15971","article-title":"Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy","volume":"52","author":"Br\u00f6ms","year":"2020","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107792_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/13524585231161492","article-title":"Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: results from a population-based cohort study","volume":"29","author":"Fink","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.phrs.2025.107792_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000723","article-title":"Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.phrs.2025.107792_bib40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semarthrit.2021.06.005","article-title":"Pregnancy outcomes in patients treated with belimumab: report from real-world experience","volume":"51","author":"Kao","year":"2021","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.phrs.2025.107792_bib41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ajog.2022.07.037","article-title":"Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials","volume":"227","author":"Sewell","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2025.107792_bib42","first-page":"287","article-title":"Challenges in conducting clinical research studies in pregnant women","volume":"47","author":"McKiever","year":"2020","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.phrs.2025.107792_bib43","unstructured":"Pregnant women: scientific and ethical considerations for inclusion in clinical trials. Food and Drug Administration 2018. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pregnant-women-scientific-and-ethical-considerations-inclusion-clinical-trials\u3009."},{"key":"10.1016\/j.phrs.2025.107792_bib44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/1471-0528.17093","article-title":"Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: a systematic review and meta-analysis","volume":"129","author":"O\u2019Byrne","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.phrs.2025.107792_bib45","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies","volume":"59","author":"Tsao","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2025.107792_bib46","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.4049\/jimmunol.0903296","article-title":"Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR","volume":"184","author":"Suzuki","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.107792_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.621247","article-title":"Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road","volume":"12","author":"Beltagy","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.107792_bib48","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding\u2014Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatol. (Oxf. )"},{"key":"10.1016\/j.phrs.2025.107792_bib49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ajg.2012.430","article-title":"Safety of thiopurines and anti-TNF-\u03b1 drugs during pregnancy in patients with inflammatory bowel disease","volume":"108","author":"Casanova","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib50","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","article-title":"Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety","volume":"65","author":"De Lima","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2025.107792_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2025.107792_bib52","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib53","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cgh.2017.02.041","article-title":"Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study","volume":"15","author":"Kanis","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2025.107792_bib54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2025.107792_bib55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.MIB.0000440984.86659.4f","article-title":"Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children","volume":"20","author":"Bortlik","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2025.107792_bib56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib57","article-title":"Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants","volume":"9","author":"Kattah","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2025.107792_bib59","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2025.107792_bib60","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.7326\/M22-0819","article-title":"Benefits and risks associated with continuation of anti-tumor necrosis factor after 24 weeks of pregnancy in women with inflammatory bowel disease: a nationwide emulation trial","volume":"175","author":"Meyer","year":"2022","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.phrs.2025.107792_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.07.028","article-title":"Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-tumor necrosis factor","volume":"20","author":"Meyer","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2025.107792_bib62","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study","volume":"16","author":"Mitrova","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2025.107792_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107792_bib64","article-title":"Inflammatory bowel disease therapies and pregnancy and neonatal outcomes: results from the PIANO registry","volume":"45","author":"Odufalu","year":"2021","journal-title":"Pr. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2021.100518","article-title":"Exposure to biologic therapy and associated maternal and neonatal outcomes in pregnancies complicated by inflammatory bowel disease","volume":"4","author":"Rekawek","year":"2022","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"10.1016\/j.phrs.2025.107792_bib66","article-title":"Immune function in newborns with in-utero exposure to anti-TNF\u03b1 therapy","volume":"10","author":"Weiss","year":"2022","journal-title":"Front Pedia"},{"key":"10.1016\/j.phrs.2025.107792_bib67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","article-title":"Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease","volume":"40","author":"Seirafi","year":"2014","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107792_bib68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107792_bib69","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Skorpen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2025.107792_bib70","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2025.107792_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.14309\/ajg.0000000000000910","article-title":"Biologics during pregnancy in women with inflammatory bowel disease and risk of infantile infections: a systematic review and meta-analysis","volume":"116","author":"Gubatan","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107792_bib73","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.medmal.2017.05.002","article-title":"Respiratory infections associated with anti-TNF\u03b1 agents","volume":"47","author":"Blanchard","year":"2017","journal-title":"Med Mal. Infect."},{"key":"10.1016\/j.phrs.2025.107792_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.980868","article-title":"Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy","volume":"12","author":"Ha","year":"2022","journal-title":"Front Cell Infect. Microbiol"},{"key":"10.1016\/j.phrs.2025.107792_bib75","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/s10165-005-0454-2","article-title":"Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor \u03b1 neutralizing antibody","volume":"16","author":"Mori","year":"2006","journal-title":"Mod. Rheuma"},{"key":"10.1016\/j.phrs.2025.107792_bib76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1159\/000450676","article-title":"Severe acute respiratory distress syndrome during infliximab therapy in a patient with Crohn disease","volume":"10","author":"Schoehl","year":"2016","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.phrs.2025.107792_bib77","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case\u2013control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.phrs.2025.107792_bib78","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2025.107792_bib79","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.107792_bib80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","article-title":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data","volume":"15","author":"Quartuccio","year":"2019","journal-title":"J. Adv. Res"},{"key":"10.1016\/j.phrs.2025.107792_bib81","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40259-024-00696-9","article-title":"Sequelae of b-cell depleting therapy: an immunologist\u2019s perspective","volume":"39","author":"Kacar","year":"2025","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.phrs.2025.107792_bib82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41584-019-0240-8","article-title":"Stratifying management of rheumatic disease for pregnancy and breastfeeding","volume":"15","author":"Giles","year":"2019","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.phrs.2025.107792_bib83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr. Epidemiol. Rep."},{"key":"10.1016\/j.phrs.2025.107792_bib84","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825002178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825002178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T23:08:16Z","timestamp":1764976096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":84,"alternative-id":["S1043661825002178"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107792","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric infections in the first year of life following maternal biologic exposure for autoimmune disorder treatment: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107792"}}